会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE
    • 乙基3S- [[4 - [[4-(氨基亚氨基)苯基]氨基] -1,4-二氧代丁基]氨基] -4-戊酸的制备方法
    • WO1997003947A1
    • 1997-02-06
    • PCT/US1996010658
    • 1996-07-12
    • G.D. SEARLE & CO.BABIAK, Kevin, A.BABU, SrinivasanBEHLING, James, R.BOYS, Mark, L.CAIN-JANICKI, Kimberly, J.DOUBLEDAY, Wendell, W.FARID, PaymanHAGEN, Timothy, J.HALLINAN, E., AnnHANSEN, Donald, W., Jr.KORTE, Donald, E.MC LAUGHLIN, Kathleen, T.MEDICH, John, R.NUGENT, Sean, T.ORLOVSKI, VlasdislavPARK, Jung, M.PETERSON, Karen, B.PILIPAUSKAS, Daniel, R.PITZELE, Barnett, S.TSYMBALOV, SofyaSTAHL, Glenn, L.
    • G.D. SEARLE & CO.
    • C07C249/12
    • C07C227/12C07C227/34C07C257/18
    • The present invention relates to a novel process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)-phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate and pharmaceutically acceptable acid addition salt thereof which comprises treating (trimethylsilyl)acetylene sequentially with n-butyllitium and 4-formylmorpholine followed by acid hydrolysis to give 3-(trimethylsilyl)-2-propynal; treating 3-(trimethylsilyl)-2-propynal with lithium bis(trimethylsilyl)amide to give in situ N,3-bis(trimethylsilyl)-2-propyn-1-imine; condensation of N,3-bis(trimethylsilyl)-2-propyn-1-imine with lithium t-butyl acetate to give (+/-)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate; treating (+/-)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate- with p-toluenesulfonic acid to give (+/-)1,1-dimethylethyl 3-amin-5-(trimethylsilyl)-4-pentynoate, mono p-toluenesulfonic acid salt, treatment of resulting salt with ethanol in the presence of p-toluenesulfonic acid to give (+/-)ethyl 3-amino-5-(trimethylsilyl)-4-pentynoate; desilylation of (+/-)ethyl 3-amino-5-(trimethylsilyl)-4-pentynoate to give in situ (+/-)ethyl 3-amino-4-pentynoate; resolution of (+/-)ethyl 3-amino-4-pentynoate using (R)-(-)-mandelic acid and treatment of the resolved product with gaseous hydrochloric acid to give ethyl 3S-amino-4-pentynoate, monohydrochloride; coupling the ethyl 3S-amino-4-pentynoate, monohydrochloride to 4-[[4-(aminoiminomethyl)phenyl]amino]-4-oxobutanoic acid, monohydrochloride in the presence of isobutyl chloroformate and N-methylmorpholine to give ethyl 3S-[[4-[[4-(aminoiminomehtyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate, monohydrochloride.
    • 本发明涉及制备3S - [[4 - [[4-(氨基亚氨基甲基) - 苯基]氨基] -1,4-二氧代丁基]氨基] -4-戊酸乙酯和药学上可接受的酸加成盐的新方法 其包括依次用正丁基鎓和4-甲酰基吗啉处理(三甲基甲硅烷基)乙炔,然后酸水解,得到3-(三甲基甲硅烷基)-2-丙炔醛; 用双(三甲基甲硅烷基)氨基锂处理3-(三甲基甲硅烷基)-2-丙炔醛,得到原位N,3-二(三甲基甲硅烷基)-2-丙炔-1-亚胺; N,3-二(三甲基甲硅烷基)-2-丙炔-1-亚胺与乙酸叔丁酯的缩合得到3-氨基-5-(三甲基甲硅烷基)-4-戊炔酸(+/-)1,1-二甲基乙酯; 用对甲苯磺酸处理(+/-)3-氨基-5-(三甲基甲硅烷基)-4-戊酸乙酯(+/-)1,1-二甲基乙基酯,得到3-氨基-5-(三甲基甲硅烷基 )-4-戊酸酯,单对甲苯磺酸盐,在对甲苯磺酸存在下用乙醇处理所得的盐,得到(+/-)3-氨基-5-(三甲基甲硅烷基)-4-戊酸乙酯; (+/-)乙基3-氨基-5-(三甲基甲硅烷基)-4-戊酸乙酯脱甲硅烷基,得到原位(+/-)3-氨基-4-戊酸乙酯; 使用(R) - ( - ) - 扁桃酸分解(+/-)乙基3-氨基-4-戊炔酸,并用气态盐酸处理分离产物,得到3S-氨基-4-戊酸乙酯,一盐酸盐; 将3S-氨基-4-戊酸乙酯,一盐酸盐在氯甲酸异丁酯和N-甲基吗啉存在下,将4 - [[4-(氨基亚氨基甲基)苯基]氨基] -4-氧代丁酸单盐酸盐偶合,得到3S- [ 4 - [[4-(氨基亚氨基甲基)苯基]氨基] -1,4-二氧代丁基]氨基] -4-戊酸乙酯,一盐酸盐。
    • 9. 发明申请
    • AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS
    • 氨氮衍生物作为氮氧化物合成酶抑制剂有用
    • WO1995025717A1
    • 1995-09-28
    • PCT/US1995003589
    • 1995-03-24
    • G.D. SEARLE & CO.CURRIE, Mark, G.WEBBER, KeithTJOENG, Foe, S.FOK, Kam, F.
    • G.D. SEARLE & CO.
    • C07C257/14
    • C07C257/14C07C391/00
    • There is disclosed amidino derivatives of formula (I), pharmaceutical compositions containing these derivatives, and their use in therapy, in particular their use as nitric oxide synthase inhibitors wherein: X is alkyl, alkenyl, alkynyl, -(CH2)kQ(CH2)l- where k is 2 or 3, l is 1 or 2 and Q is 0, Se SiY2 where Y is alkyl, S(O)z where z is 0, 1 or 2, NR where R is hydrogen or alkyl, or -(CH2)mA(CH2)n- where m is 0, 1 or 2, n is 0, 1 or 2, A is 3 to 6 membered aromatic hydrocarbon radical or 3 to 6 membered heterocyclic radical wherein 1 to 3 hetero atoms are oxygen, sulfur or nitrogen and wherein all said radicals may optionally be substituted by one or more substituents such as alkyl, alkoxy, hydroxy, halogen, nitro, cyano, trifluoroalkyl and amino; R1 may be a bond to X or hydrogen (when Q is Se), hydroxyalkyl, alkyl, alkenyl, alkynyl or haloalkyl and wherein all said radicals may optionally be substituted by one or more substituents such as alkyl, alkoxy, hydroxy, halogen, nitro, cyano, trifluoroalkyl and amino; R2 is alkyl, alkenyl, alkynyl, aromatic hydrocarbon radical, haloalkyl, hydroxylamine or heterocyclic radical wherein 1 to 3 hetero atoms are oxygen, sulfur or nitrogen and wherein all said radicals may optionally be substituted by one or more substituents such as alkyl, alkoxy, hydroxy, halogen, nitro, cyano, trifluoroalkyl and amino; and R3 is amino, alkylamine, amino acid, hydroxy, alkoxy, tetrazole or tetrazoloamine.
    • 公开了式(I)的脒基衍生物,含有这些衍生物的药物组合物及其在治疗中的用途,特别是其用作一氧化氮合酶抑制剂,其中:X为烷基,烯基,炔基, - (CH2)kQ(CH2) 其中k是2或3,l是1或2,Q是0,Se SiY2其中Y是烷基,S(O)z,其中z是0,1或2,NR,其中R是氢或烷基,或 - (CH2)mA(CH2)n-,其中m为0,1或2,n为0,1或2,A为3至6元芳族烃基或3至6元杂环基,其中1至3个杂原子为氧 ,硫或氮,并且其中所有所述基团可任选被一个或多个取代基如烷基,烷氧基,羟基,卤素,硝基,氰基,三氟烷基和氨基取代; R 1可以是与X或氢的键(当Q是Se时),羟基烷基,烷基,烯基,炔基或卤代烷基,并且其中所有所述基团可任选地被一个或多个取代基例如烷基,烷氧基,羟基,卤素,硝基 ,氰基,三氟烷基和氨基; R 2是烷基,烯基,炔基,芳族烃基,卤代烷基,羟胺或杂环基,其中1至3个杂原子是氧,硫或氮,并且其中所有所述基团可以任选地被一个或多个取代基取代,例如烷基,烷氧基, 羟基,卤素,硝基,氰基,三氟烷基和氨基; 和R3是氨基,烷基胺,氨基酸,羟基,烷氧基,四唑或四唑胺。